Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026
Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Fineline Cube Jan 22, 2026
Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Fineline Cube Jan 22, 2026
Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026
Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026
Company

GSK’s Q1 2024 Results Beat Forecasts with 10% YOY Revenue Increase; Upgrades Full-Year Outlook

Fineline Cube May 7, 2024

GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the first...

Company

Eli Lilly & Co. Raises Full-Year Guidance on Strength of Q1 2024 Results and Production Expansion

Fineline Cube May 7, 2024

Eli Lilly & Co. (NYSE: LLY) has reported financial results for the first quarter of...

Company

Pfizer Appoints Citigroup’s Andrew Baum as Executive Vice-President for Strategy and Innovation

Fineline Cube May 7, 2024

Pfizer Inc. (NYSE: PFE) has announced the appointment of Andrew Baum, M.D., to serve as...

Company Drug

EyePoint Pharmaceuticals’ Durvayu Fails to Meet Primary Endpoint in NPDR Trial

Fineline Cube May 7, 2024

EyePoint Pharmaceuticals Inc., (NASDAQ: EYPT) has announced that its drug candidate Durvayu (vorolanib intravitreal insert;...

Company

Pfizer’s Q1 2024 Results Highlight Robust Portfolio Growth and Profitability

Fineline Cube May 6, 2024

Pfizer Inc. (NYSE: PFE) saw its share price surge over 5% following the release of...

Company Policy / Regulatory

US Legislature Reviews BioSecurity Bill to Sever Biotech Industry Ties with Chinese Companies

Fineline Cube May 6, 2024

On May 15, 2024, the US House Oversight Committee is set to review a “BioSecurity”...

Company Drug

Kelun-Biotech’s RET Inhibitor A400 Advances to Phase II Trial with FDA Approval

Fineline Cube May 6, 2024

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a Chinese pharmaceutical company, has announced that its...

Company Drug

Everest Medicines’ Nefecon Secures Market Approval for IgAN Treatment in Hong Kong

Fineline Cube May 6, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, announced that it has received market approval...

Company Medical Device

Wondfo Biotech’s WELLlife Test Kit Receives FDA Nod for Home Use in the US

Fineline Cube May 6, 2024

Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), a leading biotechnology company based in China, has...

Company Medical Device

United Imaging’s uMR Jupiter 5T Becomes First Ultra-High Frequency MRI System to Gain FDA Approval

Fineline Cube May 6, 2024

Shanghai-based medical equipment manufacturer United Imaging Healthcare (UIH, SHA: 688271) has announced that it has...

Company Drug

HuidaGene’s MECP2 Duplication Syndrome Therapy Earns Positive EMA Opinion

Fineline Cube May 6, 2024

HuidaGene (Shanghai) Biotechnology Co., Ltd, a biotech company based in China, has announced that it...

Company Drug

Hansoh Pharmaceutical Secures Exclusive Rights to QYuns Therapeutics’ QX004N in Greater China

Fineline Cube May 6, 2024

Jiangsu QYuns Therapeutics Co., Ltd, a biopharmaceutical company based in China, has entered into a...

Company Deals Medical Device

Well Lead Medical’s Stone Removal Sheath Gains Karl Storz as US Sole Agent

Fineline Cube May 6, 2024

Well Lead Medical Co., Ltd (SHA: 603309), a Guangzhou-based specialist in medical catheters, has entered...

Company

Shenzhen Hepalink Logs 5.55% Q1 Revenue Growth and 133% Net Profit Increase

Fineline Cube May 6, 2024

Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced its financial results for the...

Company

Zhejiang Hisun Pharmaceutical’s Ex-President Li Yan Investigated for Graft

Fineline Cube May 6, 2024

Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a Chinese pharmaceutical company, has announced that Li...

Company Drug

Jacobio Pharma’s Glecirasib Shows Promise in Phase II Study for NSCLC Presented at ASCO

Fineline Cube May 6, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the presentation of...

Company Drug

BeiGene’s Anti-PD-1 Therapy Tislelizumab Expands Indication for Gastric Cancer in China

Fineline Cube May 6, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that its anti-PD-1 therapy, tislelizumab, has...

Company Medical Device Policy / Regulatory

China’s National Procurement Office Announces Continuous VBP for Joint Prosthetics

Fineline Cube May 6, 2024

The National High-Value Medical Consumables Joint Procurement Office in China has initiated a new round...

Company Drug

China’s NMPA Approves Shenzhen Chipscreen’s Chidamide for DLBCL Indication

Fineline Cube May 6, 2024

Shenzhen Chipscreen Biosciences Co., Ltd, a biopharmaceutical company based in China, announced that it has...

Company Deals

Siemens Healthineers AG Partners with Haidian District Government to Boost Medical Innovation in Beijing

Fineline Cube May 6, 2024

Siemens Healthineers AG (ETR: SHL), a leading medical technology company based in Germany, has entered...

Posts pagination

1 … 313 314 315 … 613

Recent updates

  • China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy
  • Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline
  • AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal
  • Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda
  • Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.